Patents Examined by Ruth A. Davis
  • Patent number: 10842824
    Abstract: Disclosed herewith is a method for inducing angiogenesis using modified placental tissue or an extract thereof to treat conditions other than cardiovascular conditions.
    Type: Grant
    Filed: July 19, 2018
    Date of Patent: November 24, 2020
    Assignee: MIMEDX GROUP, INC.
    Inventor: Thomas J. Koob
  • Patent number: 10842831
    Abstract: The present disclosure provides methods, systems, compositions, and kits to address the need for microbiome-related treatment of health conditions and disease. The present disclosure provides for treatment of metabolic conditions using microbial compositions.
    Type: Grant
    Filed: October 12, 2018
    Date of Patent: November 24, 2020
    Assignee: Pendulum Therapeutics, Inc.
    Inventors: Colleen Cutcliffe, John S. Eid, James H. Bullard, Marcus F. Schicklberger
  • Patent number: 10842830
    Abstract: The present disclosure provides methods, systems, compositions, and kits to address the need for microbiome-related treatment of health conditions and disease. The present disclosure provides for treatment of metabolic conditions using microbial compositions.
    Type: Grant
    Filed: October 12, 2018
    Date of Patent: November 24, 2020
    Assignee: Pendulum Therapeutics, Inc.
    Inventors: Colleen Cutcliffe, John S. Eid, James H. Bullard, Marcus F. Schicklberger
  • Patent number: 10822469
    Abstract: Compositions and methods of making a culture medium from a polymeric material are described herein. The method can include (a) depolymerizing and/or dispersing the polymeric material to obtain a depolymerized and/or dispersed residue, and (b) combining the depolymerized and/or dispersed residue with one or more adjuvants to form a culture medium. In some embodiments, the polymeric material can be a plastic article, such as a waste carpet material. Culture media prepared from the compositions and methods are also described. The culture media are suitable for culturing microorganisms including bacterium, algae, and fungus. The microorganisms can be used to produce a bioproduct such as a biopolymer, an enzyme, or a cellular metabolite.
    Type: Grant
    Filed: August 4, 2016
    Date of Patent: November 3, 2020
    Assignee: Georgia State University Research Foundation, Inc.
    Inventors: Bryan Stubblefield, Eric Gilbert
  • Patent number: 10814033
    Abstract: The present application relates to use of transglutaminases to treat various products, including medical devices such as tissue grafts, tissue matrices or other tissue-derived materials, and synthetics. The transglutaminases can be applied to the medical devices to provide advantages such as adhesion resistance or abrasion resistance.
    Type: Grant
    Filed: August 21, 2019
    Date of Patent: October 27, 2020
    Assignee: LifeCell Corporation
    Inventors: Yi Chen, Sean Collins, Li Ting Huang, Eric Stec, Hui Xu
  • Patent number: 10815393
    Abstract: A gelatin or a chemically modified product thereof contains 10 to 50% by mass of a high-molecular weight component, and a low-molecular weight component in such an amount that a value obtained by subtracting a low-molecular weight component content from a high-molecular weight component content is greater than or equal to 0% by mass.
    Type: Grant
    Filed: October 18, 2016
    Date of Patent: October 27, 2020
    Assignees: TOKYO METROPOLITAN INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE, NITTA GELATIN INC.
    Inventors: Yoshimi Ohyabu, Shunji Yunoki, Hirosuke Hatayama, Masataka Ida, Yosuke Hiraoka
  • Patent number: 10806824
    Abstract: Methods and compositions for the biological repair of cartilage using a hybrid construct combining both an inert structure and living core are described. The inert structure is intended to act not only as a delivery system to feed and grow a living core component, but also as an inducer of cell differentiation. The inert structure comprises concentric internal and external and inflatable/expandable balloon-like bio-polymers. The living core comprises the cell-matrix construct comprised of HDFs, for example, seeded in a scaffold. The method comprises surgically removing a damaged cartilage from a patient and inserting the hybrid construct into the cavity generated after the foregoing surgical intervention. The balloons of the inert structure are successively inflated within the target area, such as a joint, for example. Also disclosed herein are methods for growing and differentiating human fibroblasts into chondrocyte-like cells via mechanical strain.
    Type: Grant
    Filed: July 18, 2018
    Date of Patent: October 20, 2020
    Assignee: SpinalCyte, LLC
    Inventors: Lionel C. Sevrain, Sylvie Y. Verdier-Sevrain
  • Patent number: 10808220
    Abstract: A method of making a porous three-dimensional graphene mesh includes combining a graphene-containing material and a polymer having a plurality of hydroxyl groups in an alcohol solvent to form a mixture, adding a salt to the mixture, heating the mixture to form a gel, and washing the gel with water to remove the salt from the gel, leaving behind stable pores to form a scaffold. A three-dimensional porous graphene mesh includes a graphene-containing material and a polymer. The polymer is crosslinked with the graphene-containing material such that the Young's Modulus of the mesh is at least about 5 GPa.
    Type: Grant
    Filed: March 9, 2018
    Date of Patent: October 20, 2020
    Assignee: University of North Dakota
    Inventors: Ying Zhang, Julia Xiaojun Zhao, Diane Darland
  • Patent number: 10792411
    Abstract: Provided is an accelerated method for preparing platelet rich plasma (PrP) without centrifugation or filtration. The method comprises contacting a sample of whole blood with an anti-coagulant and an inducer of Rouleaux formation; allowing the mixture to stand thereby depleting the sample of RBCs, and collecting the platelet-rich plasma fraction. The PrP volume obtained by the present method is about 10-60% of the volume of the starting whole blood sample, and contains less than 200,000 RBCs and at least 100,000 platelets per microliter.
    Type: Grant
    Filed: May 9, 2017
    Date of Patent: October 6, 2020
    Inventors: Jae-Hyung Robert Chang, Giuseppe Intini
  • Patent number: 10791730
    Abstract: This invention provides for compositions for cryopreservation of human umbilical cord tissue-derived cells. The cryopreservation compositions may comprise: (a) amino acids; (b) vitamins; (c) inorganic salts; and (d) DMSO, sucrose, mannitol, and lactobionic acid. The invention also provides for kits comprising the composition and human umbilical cord tissue-derived cells and methods of cryopreserving the cells, which utilize the compositions.
    Type: Grant
    Filed: January 6, 2017
    Date of Patent: October 6, 2020
    Assignee: DEPUY SYNTHES PRODUCTS, INC.
    Inventors: Anna Gosiewska, Anthony J. Kihm
  • Patent number: 10780137
    Abstract: The present invention relates to compositions comprising at least about 8% ?-glucans and/or at least about 8% ?-fucans, which has a prebiotic effect and act as a replacement for in-feed antibiotics. The present invention also relates to extraction methods to obtain such extracts and various uses for the compositions comprising ?-glucans and/or ?-fucans.
    Type: Grant
    Filed: July 8, 2019
    Date of Patent: September 22, 2020
    Assignee: Bioatlantis Limited
    Inventors: John O'Doherty, John T. O'Sullivan
  • Patent number: 10758599
    Abstract: The present invention relates to formulations of ADAMTS13 with enhanced or desirable properties. As such, the invention provides liquid and lyophilized formulations of ADAMTS13 that are suitable for pharmaceutical administration. Among other aspects, the present invention also provides methods of treating various diseases and conditions related to VWF and/or ADAMTS13 dysfunction in a subject. Also provided herein are kits comprising ADAMTS13 formulations useful for the treatment of various diseases and conditions.
    Type: Grant
    Filed: February 14, 2019
    Date of Patent: September 1, 2020
    Assignees: Baxalta Incorporated, Baxalta GmbH
    Inventors: Peter Matthiessen, Peter L. Turecek, Hans-Peter Schwarz
  • Patent number: 10760113
    Abstract: The invention provides cellular assays for detecting the activity of one or more kinase from multiple conditions simultaneously, by encoding biochemically identical substrates with isotope labels that enable them to be distinguished in pooled samples by mass spectrometry.
    Type: Grant
    Filed: July 11, 2016
    Date of Patent: September 1, 2020
    Assignees: REGENTS OF THE UNIVERSITY OF MINNESOTA, PURDUE RESEARCH FOUNDATION
    Inventors: Laurie L. Parker, Tzu-Yi Yang, Vincent Davisson
  • Patent number: 10760068
    Abstract: A hydrogel precursor formulation which is in the form of an unreacted powder. The formulation comprises an activating enzyme, preferably thrombin, a cross-linking enzyme, preferably a transglutaminase, and more preferably factor XIII transglutaminase. The cross-linking enzyme is activatable by the activating enzyme in water with or without a buffer, and at least one structural compound A. The structural compound is crosslinkable by a selective reaction mediated by the crosslinking enzyme to form a hydrogel, wherein the cross-linking enzyme is activated.
    Type: Grant
    Filed: July 20, 2017
    Date of Patent: September 1, 2020
    Assignee: QGEL SA
    Inventors: Simone Rizzi, Jeremy Touati
  • Patent number: 10751371
    Abstract: Provided are uses of allogeneic interstitial vessel-layer cells and allogeneic mesenchymal progenitor cells in the preparation of a pharmaceutical composition for preventing or treating osteoarthritis (OA). Also provided is a pharmaceutical composition containing the allogeneic interstitial vessel-layer cells and the allogeneic mesenchymal progenitor cells.
    Type: Grant
    Filed: April 6, 2018
    Date of Patent: August 25, 2020
    Assignees: Cellular Biomedicine Group (Shanghai) Ltd., Cellular Biomedicine Group (Wuxi) Ltd.
    Inventors: Wei Cao, Xiaoling Zeng, Mohammad Abdul Kaium, Yujie Zhou
  • Patent number: 10745718
    Abstract: In ethyl alcohol production using the self-fermentation of a microalga, a step of concentrating or collecting an algal body by centrifugal treatment, filtering treatment or the like is made unnecessary or simple to save labor for effort and equipment therefor is saved. The microalga belongs to Chlamydomonas sp., and is a variant strain which has an ability to produce ethyl alcohol under dark and anaerobic conditions and has acquired an ability to proliferate while aggregating. The microalga is proliferated and maintained under dark and anaerobic conditions to generate ethyl alcohol in this method for producing ethyl alcohol.
    Type: Grant
    Filed: April 21, 2017
    Date of Patent: August 18, 2020
    Assignee: HONDA MOTOR CO., LTD.
    Inventors: Nozomi Shiobara, Shohei Kinoshita
  • Patent number: 10736927
    Abstract: The present invention relates to methods and pharmaceutical compositions for preventing or treating inflammatory bowel diseases.
    Type: Grant
    Filed: August 22, 2016
    Date of Patent: August 11, 2020
    Assignees: INSERM (INSTITUTE NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MEDICALE), UNIVERSITÉ PIERRE ET MARIE CURIE (PARIS 6), INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP)
    Inventors: Harry Sokol, Mathias Lavie-Richard, Marie-Laure Michel, Bruno Michel Lamas, Philippe Langella
  • Patent number: 10725043
    Abstract: Provided are a three-dimensional (3D) fibroblast cluster, a method of preparing the same, an in vitro 3D skin dermis model including a fibroblast cluster cultured from a fibroblast, and a method of screening a drug by using the in vitro 3D skin dermis model.
    Type: Grant
    Filed: April 19, 2016
    Date of Patent: July 28, 2020
    Assignee: S-BIOMEDICS
    Inventors: Sang Heon Kim, Jong Hoon Choi, Kwi Deok Park
  • Patent number: 10722543
    Abstract: Methods of inhibiting or reducing tumor metabolism and growth are disclosed. A composition containing oxygen scavenging membrane fragments and anaerobe bacteria is injected into a tumor to interfere with tumor growth and metabolism, leading to tumor necrosis. The composition may also contain a cryoprotectant, which permits the composition to be stored at sub-zero temperatures without freezing.
    Type: Grant
    Filed: January 26, 2017
    Date of Patent: July 28, 2020
    Assignee: Oxyrase, Inc.
    Inventor: James C. Copeland
  • Patent number: 10711247
    Abstract: The present invention pertains to a method for culturing a cell population including pluripotent stem cells and differentiated cells derived from pluripotent stem cells at a temperature of 40.5° C. or higher and reducing the pluripotent stem cells included in the cell population. The present invention also pertains to a method for reducing pluripotent stem cells from a cell population including pluripotent stem cells and differentiated cells derived from pluripotent stem cells, wherein the method includes a step for activating the TRPV-1 expressed in the pluripotent stem cells included in the cell population. The present invention makes it possible to reduce the pluripotent stem cells remaining in an undifferentiated state when inducing the differentiation of a pluripotent stem cell population.
    Type: Grant
    Filed: August 23, 2016
    Date of Patent: July 14, 2020
    Assignee: TOKYO WOMEN'S MEDICAL UNIVERSITY
    Inventors: Katsuhisa Matsuura, Tatsuya Shimizu, Hiroyoshi Seta